Organisation paid for research Program year 2023 Source: CMS Open Payments

Stephen E Smith MD PA

Neither a doctor nor a teaching hospital

Research payments

$78,604

21 payments

Through program year 2023, Stephen E Smith MD PA is reported as receiving $78,604 in research payments, across 21 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$649	2
2022	Research	$7,972	3
2021	Research	$3,610	4
2019	Research	$66,373	12

Breakdown

Who paid Research payments · program years 2019–2023

Allergan Inc. $66,373 12 payments
AbbVie, Inc. $8,621 5 payments
Glaukos Corporation $3,610 4 payments

Studies the money was for Research payments · program years 2019–2023

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension $50,274 2 payments
The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension $8,384 7 payments
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertension $7,715 3 payments
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia $7,120 2 payments
Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream 4, 6 and 8 BID for the Treatment of Signs and Symptoms of Dry Eye Disease $3,610 4 payments
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) $852 1 payment
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS) $602 1 payment
Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension $47 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.